Kazia Therapeutics Shares Are Trading Lower, After Initally Spiking Higher, Amid Increased Volatility in the Stock After the Company Announced the Early Conclusion of the Phase 1 Paxalisib Trial in Solid Tumors After Reaching the Primary Endpoint
Kazia Therapeutics在達到主要終點後宣佈實體瘤Paxalisib第一階段試驗提前結束後，股價波動性加大，此前該公司股價在最初飆升後交易走低